Want to meet at the event? Reach out: www.lunaibioworks.com/contact. Learn more: www.biosymetrics.com and www.lunaibioworks.com

Our team also supports biomarker discovery, trial enrichment, and in vivo validation, so teams can get earlier readouts on efficacy and safety and reduce risk in decisions about what to advance.

With the Augusta platform, our team helps pharma teams turn real-world and clinical data into actionable insights, including patient subtyping and disease stratification.

Meet us at the AWS Life Sciences Symposium, April 14, 2026, Javits Center, NYC – BioSymetrics/Lunai Bioworks

Our subsidiary, BioSymetrics, is heading to the AWS Life Sciences Symposium in NYC on Tuesday, April 14 at the Javits Center. If you’re attending, let’s connect. #LifeSciences #DrugDiscovery #AWS

Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ: LNAI), an AI-driven drug discovery and biodefense company, today announced that its subsidiary, BioSymetrics, has...

Read the full announcement: www.prnewswire.com/news-release.... Learn more at www.biosymetrics.com and www.lunaibioworks.com.

The screening systems are designed to evaluate hundreds to thousands of compounds per week. We integrate biological results with computational modeling to improve characterization and support defense readiness.

The work combines zebrafish-based phenotypic screening with AI-driven mechanism-of-action prediction to speed up identification and classification of neuroactive and neurotoxic compounds.

A defense collaboration for chemical threat assessment using BioSymetrics' AI platform – BioSymetrics/Lunai Bioworks

BioSymetrics (a Lunai Bioworks company) has entered a commercial defense collaboration to build an AI-enabled platform for chemical threat assessment. Work is underway, with additional opportunities under discussion. #Biodefense #ChemicalThreats #MachineLearning

LUNAI Harnessing phenomics and AI to turn disease signals into new therapies. We uncover treatments by reading disease in motion, decoded by AI, confirmed in living systems, built for patients.

Learn more about Lunai Bioworks: www.lunaibioworks.com

Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications Lunai Bioworks, Inc. (NASDAQ: LNAI) today announced it has executed a binding $20 million strategic transaction to acquire blood-brain barrier (BBB) delivery technology and central nervous system (CNS...

Read the press release: ir.lunaibioworks.com/news/news-de...

This acquisition supports a more complete pipeline from drug discovery to in vivo validation and brain delivery. This pipeline combines biology insight with a validated mechanism designed to deliver therapies directly into the brain.

The underlying chemistry is designed to help compounds cross the BBB, remain inactive in the body, and then activate inside the brain. The mechanism targets pathways linked to acetylcholinesterase modulation.

Lunai Bioworks acquires blood-brain barrier delivery platform for central nervous system Alzheimer’s therapies

Lunai Bioworks (NASDAQ: LNAI) has announced a $20M transaction to acquire blood-brain barrier (BBB) delivery technology and CNS Alzheimer’s drug assets from the Clemann Group. BBB delivery is a major bottleneck in CNS drug development. #Alzheimers #CNS #BloodBrainBarrier

Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model Lunai Bioworks (NASDAQ: LNAI), through its wholly owned subsidiary BioSymetrics, today announced the formation of a national consortium designed to accelerate the discovery and development of chemical...

Read the press release: ir.lunaibioworks.com/news/news-de.... Learn more about us: www.biosymetrics.com and www.lunaibioworks.com.

Collaborators include Calum MacRae (Brigham and Women’s Hospital; Harvard Medical School), Vik Bebarta (@vikbebarta.bsky.social; University of Colorado), Randall Peterson (University of Utah), and Vincent Jo Davisson (Purdue University).

The model targets an ~36-month path: early efficacy in yeast/cell systems, validation in FDA-recognized zebrafish models, confirmatory animal studies, and a ~50-person Phase I safety study.

Pathfinder brings together capabilities that have historically operated in separate silos, including academic research, military research, federal stakeholders, and biotech, into a coordinated framework built for speed.

A national chemical defense consortium targeting $400M–$1.2B countermeasure programs with a 3-year AI counteragent development model – BioSymetrics/Lunai Bioworks

Lunai Bioworks (NASDAQ: LNAI), through our subsidiary BioSymetrics, has launched the Pathfinder Consortium, a national academic-industry alliance designed to accelerate medical countermeasures for emerging chemical threats. #Biodefense #MedicalCountermeasures #AIforDrugDiscovery

Want to meet at PMWC? Contact us here: www.lunaibioworks.com/contact

We’re sharing how Augusta couples predictive AI with high-throughput in vivo validation to help improve translational confidence for complex diseases, including neurology, alongside updates from our biodefense work.

He’ll discuss a closed-loop workflow that pairs predictive AI with high-throughput in vivo validation in neurological disease models to help prioritize hits and improve biological relevance.

Gabe Musso, our CSO, is speaking Friday, March 6, 2026 in the AI in Drug Discovery & Computational Biology track: “From Prediction to Translation: AI and In Vivo Validation to Improve Drug Development Success.”

Lunai Bioworks has landed at PMWC 2026, Silicon Valley, March 4-6. See Gabe Musso’s talk, March 6 at 11:45 a.m. PST

Lunai Bioworks has landed at PMWC 2026 in Santa Clara (Mar 4–6). If you’re working on neurology programs and care about translation-first drug discovery, we’d love to connect. #PMWC2026 #DrugDiscovery #Biodefense

These readouts are designed to shorten the cycle from in vivo experiments to insights. Learn more: www.lunaibioworks.com/alcohol-use-....

The program also aims to screen and profile small molecules, then evaluate promising compounds in appropriate mammalian ethanol exposure models.

Readouts included activity level, movement paths, edge preference, exploration diversity, heart rate, and twitches, designed to support faster iteration after in vivo experiments.

To support this project, the BioSymetrics computer vision team generated multimodal, decision-ready readouts that go beyond activity levels and movement paths.

Faster, decision-ready metrics for alcohol use disorder studies – BioSymetrics/Lunai Bioworks

In collaboration with Dr. Calum MacRae's lab at Harvard Medical School and Brigham and Women's Hospital, BioSymetrics (a @lunaibioworks.com company) is supporting an AUD project to optimize phenotyping across the addiction cycle. #AlcoholUseDisorder #DrugDiscovery #ComputerVision

We’re also building Sentinel™ for biodefense. If you want to discuss partnering or set up time at PMWC, reach us here: www.lunaibioworks.com/contact

At PMWC, we’ll be talking about Augusta, our phenomics-first platform for neurology that links patient subgroups and biomarkers to decision-grade targets. The Phenograph™ helps translate between clinical phenotypes and model-system phenotypes to guide validation.